RS54910B1 - Jedinjenje indola i njegova upotreba u farmaciji - Google Patents

Jedinjenje indola i njegova upotreba u farmaciji

Info

Publication number
RS54910B1
RS54910B1 RS20160385A RSP20160385A RS54910B1 RS 54910 B1 RS54910 B1 RS 54910B1 RS 20160385 A RS20160385 A RS 20160385A RS P20160385 A RSP20160385 A RS P20160385A RS 54910 B1 RS54910 B1 RS 54910B1
Authority
RS
Serbia
Prior art keywords
group
groups
optionally substituted
alkoxy
substituted
Prior art date
Application number
RS20160385A
Other languages
English (en)
Inventor
Teruhiko Inoue
Tetsudo Kaya
Shinichi Kikuchi
Koji Matsumura
Ritsuki Masuo
Motoya Suzuki
Michihide Maekawa
Original Assignee
Japan Tobacco Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Japan Tobacco Inc filed Critical Japan Tobacco Inc
Publication of RS54910B1 publication Critical patent/RS54910B1/sr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A61K31/416—1,2-Diazoles condensed with carbocyclic ring systems, e.g. indazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

Jedinjenje predstavljeno sledećom formulom [I], ili neka njegova farmaceutski prihvatljiva so:naznačeno time, što suR1 je(1) atom vodonika,(2) hidroksilna grupa, ili(3) C1-6 alkoksi grupa, supstituisana sa C6-10 aril grupom (grupama);R2 i R3 su iste ili različite grupe, a svaka je(1) atom vodonika, ili(2) neka C1-6 alkil grupa, opciono supstituisana sa 1 do 3 supstituenta koji se biraju između(a) hidroksilne grupe, i(b) neke C1-6 alkoksi grupe; aR4 je neka grupa predstavljena sakoja je vezana u položaju 5 ili položaju 6 prstena indola,pri čemuR5 predstavlja(1) atom vodonika, ili(2) neka C1-6 alkil grupa, a R6 predstavlja(1) atom vodonika,(2) neka C1-6 alkil grupa, opciono supstituisana sa 1 do 3 supstituenta koji se biraju između(a) hidroksi grupe,(b) neke C1-6 alkoksi grupe,(c) neke karboksi grupe,(d) neke C1-6 alkoksi-karbonil grupe,(e) neke C6-10 aril grupe,(f) neke C6-10 ariloksi grupe,(g) neke amino grupe, opciono mono- ili di-supstituisane sa C1-6 alkil grupom (grupama,(h) neke 5- ili 6-člane nezasićene heterociklične grupe, opciono supstituisane sa C1-6 alkil grupom (grupama), i(i) neke 5- ili 6-člane zasićene heterociklične grupe,(3) neka C1-6 alkoksi grupa,(4) neka C6-10 aril grupa, ili(5) neka 5- ili 6-člana nezasićena heterociklična grupa, opciono supstituisana sa 1 do 3 supstituenta koji se biraju između(a) hidroksilne grupe, i(b) neke C1-6 alkoksi grupe,iliR5 i R6 formiraju, zajedno sa atomom azota za koji su vezane, neki 5- do 6-člani ciklični amin (pomenuti ciklični amin je opciono kondenzovan sa 5- ili 6-članim nezasićenim heterociklom), opciono supstituisan sa 1 do 3 supstituenta, koji se biraju između(a) hidroksi grupe,(b) neke C1-6 alkil grupe,(c) neke C1-6 alkoksi grupe, i(d) neke C1-6 alkoksi-karbonil grupe;R7 predstavlja(1) atom vodonika, ili(2)neka C1-6 alkil grupa, opciono supstituisana sa 1 do 3 supstituenta koji se biraju između(a) hidroksi grupe,(b) neke C1-6 alkoksi grupe, i(c) neke amino grupe, opciono mono- ili di-supstituisane sa C1-6 alkil grupom (grupama, iR8 predstavlja(1) neka C1-6 alkil grupa, opciono supstituisana sa 1 do 3 supstituenta koji se biraju između(a) hidroksi grupe,(b) C1-6 alkoksi grupe, supstituisane sa C6-10 aril grupom (grupama),(c) neke C3-6 cikloalkil grupe, opciono supstituisane sa C1-6 alkoksi grupom (grupama),(d) neke C6-10 aril grupe,(e) neke 5- ili 6-člane nezasićene heterociklične grupe, opciono supstituisane sa okso grupom (grupama),(f) neke 5- do 8-člane zasićene heterociklične grupe, opciono supstituisane sa 1 do 3 supstituenta, koji se biraju između(i) hidroksi grupe,(ii) neke C1-6 alkil grupe, opciono supstituisane sa 1 do 3 supstituenta koji se biraju između hidroksi grupe i neke C1-6 alkoksi grupe,(iii) neke C1-6 alkoksi grupe, i(iv) neke okso grupe,(g) neke C3-6 cikloalkiloksi grupe,(h) neke C6-10 ariloksi grupe,(i) neke 5- ili 6-člane nezasićene heterocikliloksi grupe,(j) neke 5- ili 6-člane zasićene heterocikliloksi grupe, i(k) neke amino grupe, opciono mono- ili di-supstituisane sa supstituentima koji se biraju između(i) neke C1-6 alkil grupe, opciono supstituisane sa 1 do 3 supstituenta koji se biraju između hidroksilne grupe, neke karboksi grupe i neke karboksi C1-6 alkoksi grupe,(ii) neke C1-6 alkil-karbonil grupe, opciono supstituisane sa 1 do 3 supstituenta, koji se biraju između hidroksi grupe i neke C1-6 alkoksi grupe,(iii) neke C1-6 alkoksi-karbonil grupe, opciono supstituisane sa C6-10 aril grupom (grupama), i(iv) neke C3-6 cikloalkil-karbonil grupe, opciono supstituisane sa C1-6 alkoksi grupom (grupama),(2) C1-6 alkoksi grupa, supstituisana sa Ce-io aril grupom (grupama),(3) neka C3-6 cikloalkil grupa, opciono supstituisana sa 1 do 3 supstituenta, koji se biraju između(a) hidroksilne grupe, i(b) neke C1-6 alkoksi grupe,(4) neka C6-10 aril grupa, opciono supstituisana sa C1-6 alkil grupom (grupama), opciono supstituisanom sa 1 do 3 atoma halogena,(5) neka amino grupa, opciono mono- ili di-supstituisana sa nekom C1-6 alkil grupom (grupama), opciono supstituisanom sa C6-10 aril grupom (grupama),(6) neka 5- ili 6-člana nezasićena heterociklična grupa, opciono supstituisana sa C1-6 alkil grupom (grupama),(7) neka 5- ili 6-člana zasićena heterociklična grupa, opciono supstituisana sa 1 do 3 supstituenta, koji se biraju između(a) neke C1-6 alkil grupe,(b) neke C1-6 alkil-karbonil grupe, i(c) neke okso grupe,(8) neka C3-6 cikloalkiloksi grupa, ili(9) neka C6-10 aril-karbonil grupa,iliR7 i R8 formiraju, zajedno sa atomom ugljenika za koji su vezane, neki 5- do 6-člani ciklični amin, supstituisan sa nekom okso grupom i opciono još supstituisan sa 1 do 3 supstituenta koji se biraju između(a) hidroksi grupe,(b) neke C1-6 alkil grupe, opciono supstituisane sa hidroksi grupom (grupama),(c) neke C1-6 alkoksi grupe, i(d) neke C3-6 cikloalkil grupe.Prijava sadrži još 31 patentni zahtev.
RS20160385A 2009-11-25 2010-11-25 Jedinjenje indola i njegova upotreba u farmaciji RS54910B1 (sr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2009268040 2009-11-25
EP10833248.7A EP2505586B1 (en) 2009-11-25 2010-11-25 Indole compound and pharmaceutical use thereof
PCT/JP2010/070988 WO2011065402A1 (ja) 2009-11-25 2010-11-25 インドール化合物及びその医薬用途

Publications (1)

Publication Number Publication Date
RS54910B1 true RS54910B1 (sr) 2016-10-31

Family

ID=44066507

Family Applications (1)

Application Number Title Priority Date Filing Date
RS20160385A RS54910B1 (sr) 2009-11-25 2010-11-25 Jedinjenje indola i njegova upotreba u farmaciji

Country Status (31)

Country Link
US (6) US8299070B2 (sr)
EP (3) EP2505586B1 (sr)
JP (6) JP5734628B2 (sr)
KR (1) KR101766502B1 (sr)
CN (1) CN102712624B (sr)
AR (1) AR079164A1 (sr)
AU (1) AU2010323579C1 (sr)
BR (1) BR112012012529B1 (sr)
CA (1) CA2781660C (sr)
CL (1) CL2012001328A1 (sr)
CO (1) CO6541645A2 (sr)
CY (1) CY1117559T1 (sr)
DK (1) DK2505586T3 (sr)
ES (1) ES2572935T3 (sr)
HK (1) HK1174025A1 (sr)
HR (1) HRP20160579T1 (sr)
HU (1) HUE028016T2 (sr)
IL (1) IL220009A (sr)
ME (1) ME02447B (sr)
MX (1) MX2012006017A (sr)
MY (1) MY161095A (sr)
NZ (1) NZ600840A (sr)
PE (1) PE20121358A1 (sr)
PL (1) PL2505586T3 (sr)
PT (1) PT2505586E (sr)
RS (1) RS54910B1 (sr)
RU (1) RU2556216C2 (sr)
SI (1) SI2505586T1 (sr)
SM (1) SMT201600258B (sr)
TW (1) TWI491591B (sr)
WO (1) WO2011065402A1 (sr)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8299070B2 (en) * 2009-11-25 2012-10-30 Japan Tobacco Inc. Indole compounds and pharmaceutical use thereof
CA3113343A1 (en) 2010-06-03 2011-12-08 Pharmacyclics Llc Use of inhibitors of bruton's tyrosine kinase (btk) in the treatment of follicular lymphoma
EP3550031A1 (en) 2012-07-24 2019-10-09 Pharmacyclics, LLC Mutations associated with resistance to inhibitors of bruton's tyrosine kinase (btk)
US9717731B2 (en) * 2012-11-02 2017-08-01 Pharmacyclics Llc TEC family kinase inhibitor adjuvant therapy
CN103804364A (zh) * 2012-11-06 2014-05-21 韩冰 一类治疗缺血性脑损伤的化合物及其用途
CN103804361A (zh) * 2012-11-07 2014-05-21 韩冰 一类治疗神经退行性疾病的化合物及其用途
CN103800328A (zh) * 2012-11-07 2014-05-21 韩冰 一类治疗神经退行性疾病的化合物及其用途
CN103804291A (zh) * 2012-11-07 2014-05-21 韩冰 一类治疗神经退行性疾病的化合物及其用途
CN103800337A (zh) * 2012-11-07 2014-05-21 韩冰 一类治疗神经退行性疾病的化合物及其用途
CN103800340A (zh) * 2012-11-09 2014-05-21 韩冰 一类治疗青光眼的化合物及其用途
CN103804272A (zh) * 2012-11-14 2014-05-21 韩冰 一类具有神经保护作用的化合物及其用途
CN103804351A (zh) * 2012-11-14 2014-05-21 韩冰 一类具有神经保护作用的化合物及其用途
CN103804302A (zh) * 2012-11-14 2014-05-21 杨育新 一类治疗创伤性脑损伤疾病的化合物及其用途
CN103804363A (zh) * 2012-11-14 2014-05-21 韩冰 一类具有神经保护作用的化合物及其用途
CN104628657A (zh) * 2013-11-06 2015-05-20 韩冰 一类治疗缺血性脑损伤的化合物及其用途
WO2015143400A1 (en) 2014-03-20 2015-09-24 Pharmacyclics, Inc. Phospholipase c gamma 2 and resistance associated mutations
TW201625605A (zh) * 2014-04-04 2016-07-16 賽諾菲公司 用於治療糖尿病、肥胖、血脂異常及相關病症之作為ｇｐｒ１１９調節劑的經取代之稠合雜環類
JP6596417B2 (ja) * 2014-07-04 2019-10-23 日本たばこ産業株式会社 インドール化合物の製造方法
WO2016010108A1 (ja) * 2014-07-18 2016-01-21 塩野義製薬株式会社 含窒素複素環誘導体およびそれらを含有する医薬組成物
CN104356086A (zh) * 2014-11-28 2015-02-18 湖南科技大学 一种适于工业生产3-吗啉酮的制备方法
WO2019225740A1 (ja) 2018-05-25 2019-11-28 日本たばこ産業株式会社 インドール化合物を含む多発性硬化症の治療又は予防剤
WO2019225741A1 (ja) 2018-05-25 2019-11-28 日本たばこ産業株式会社 インドール化合物を含むネフローゼ症候群の治療又は予防剤
SI3801546T1 (sl) * 2018-05-25 2024-09-30 Japan Tobacco Inc. Indolna spojina za zdravljenje intersticijskega cistitisa
CR20220299A (es) 2019-12-20 2022-08-05 Pfizer Derivados de becimidazol
KR102270026B1 (ko) * 2020-01-31 2021-06-28 현대약품 주식회사 (3s)-3-(4-(3-(1,4-다이옥사스파이로[4,5]데스-7-엔-8-일)벤질옥시)페닐)헥스-4-이노익산의 품질 평가 방법
EP4263538A1 (en) * 2020-12-15 2023-10-25 Pfizer Inc. Pyrido[2,3-d]imidazole derivatives and their use as inhibitors of itk for the teatment of skin disease
US20240132477A1 (en) * 2020-12-15 2024-04-25 Pfizer Inc. Benzimidazole Derivatives and Their Use As Inhibitors of ITK For The Treatment of Skin Disease
US20240279202A1 (en) * 2021-05-03 2024-08-22 Nurix Therapeutics, Inc. Compounds for inhibiting or degrading itk, compositions, comprising the same methods of their making and methods of their use
JP2024517859A (ja) * 2021-05-03 2024-04-23 ニューリックス セラピューティクス，インコーポレイテッド 標的タンパク質を阻害又は分解するための化合物、それを含む組成物、それらの作製方法、及びそれらの使用方法
TW202315618A (zh) * 2021-06-11 2023-04-16 美商愛德亞生物科學公司 作為DNA聚合酶θ抑制劑之O-聯結噻二唑基化合物
CA3235182A1 (en) * 2021-10-19 2023-04-27 Kerem OZBOYA Bifunctional compounds for degrading itk via ubiquitin proteosome pathway

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US953411A (en) * 1908-09-02 1910-03-29 Erastus De Moulin Trick weight-lifting machine.
AU2002334217B2 (en) * 2001-10-26 2008-07-03 Aventis Pharmaceuticals Inc. Benzimidazoles and analogues and their use as protein kinases inhibitors
DK1474425T3 (da) * 2002-01-07 2006-09-25 Eisai Co Ltd Deazapuriner og anvendelser deraf
JP2003231687A (ja) 2002-02-04 2003-08-19 Japan Tobacco Inc ピラゾリル縮合環化合物及びその医薬用途
FR2854159B1 (fr) * 2003-04-25 2008-01-11 Aventis Pharma Sa Nouveaux derives de l'indole, leur preparation a titre de medicaments, compositions pharmaceutiques et notamment comme inhibiteurs de kdr
US20050032869A1 (en) * 2003-07-08 2005-02-10 Pharmacia Italia S.P.A. Pyrazolyl-indole derivatives active as kinase inhibitors, process for their preparation and pharmaceutical compositions comprising them
CA2538032C (en) 2003-09-08 2011-01-11 Aventis Pharmaceuticals Inc. Thienopyrazoles
US7745641B2 (en) * 2005-04-19 2010-06-29 Kyowa Hakko Kirin Co., Ltd. Nitrogen-containing heterocyclic compound
EP1968580A2 (en) * 2005-12-20 2008-09-17 Boehringer Ingelheim International Gmbh 2-(ih-thieno [3,2-c] pyrazol-3yl)-ih-indole derivatives and related compounds as tec kinase inhibitors for the treatment of inflammations and immunological disorders
GB0602178D0 (en) 2006-02-03 2006-03-15 Merck Sharp & Dohme Therapeutic treatment
EP2001480A4 (en) * 2006-03-31 2011-06-15 Abbott Lab Indazole CONNECTIONS
EP2865381A1 (en) * 2006-05-18 2015-04-29 Pharmacyclics, Inc. ITK inhibitors for treating blood cell malignancies
WO2008047831A1 (fr) * 2006-10-17 2008-04-24 Kyowa Hakko Kirin Co., Ltd. Inhibiteurs de JAK
CA2668744C (en) 2006-11-17 2015-09-15 Queen's University At Kingston Compounds and methods for treating protein folding disorders
UA99459C2 (en) 2007-05-04 2012-08-27 Астразенека Аб 9-(pyrazol-3-yl)- 9h-purine-2-amine and 3-(pyraz0l-3-yl)-3h-imidazo[4,5-b]pyridin-5-amine derivatives and their use for the treatment of cancer
JP2009268040A (ja) 2008-04-23 2009-11-12 Teruhiko Daiho ループアンテナ装置
US8299070B2 (en) * 2009-11-25 2012-10-30 Japan Tobacco Inc. Indole compounds and pharmaceutical use thereof

Also Published As

Publication number Publication date
JP2015172051A (ja) 2015-10-01
HRP20160579T1 (hr) 2016-07-29
CN102712624B (zh) 2014-06-04
CA2781660C (en) 2018-06-26
MX2012006017A (es) 2012-06-25
US20110306599A1 (en) 2011-12-15
ES2572935T3 (es) 2016-06-03
PL2505586T3 (pl) 2016-12-30
KR101766502B1 (ko) 2017-08-08
PE20121358A1 (es) 2012-10-23
JP2017039761A (ja) 2017-02-23
EP3766877A1 (en) 2021-01-20
RU2556216C2 (ru) 2015-07-10
US20170267662A1 (en) 2017-09-21
CY1117559T1 (el) 2017-04-26
EP3059234A1 (en) 2016-08-24
US8299070B2 (en) 2012-10-30
JP5734628B2 (ja) 2015-06-17
JP2018158935A (ja) 2018-10-11
AU2010323579B2 (en) 2016-05-19
JP2011132222A (ja) 2011-07-07
MY161095A (en) 2017-04-14
US20200255408A1 (en) 2020-08-13
AR079164A1 (es) 2011-12-28
AU2010323579C1 (en) 2016-11-03
IL220009A (en) 2017-08-31
HK1174025A1 (zh) 2013-05-31
CL2012001328A1 (es) 2012-10-05
CA2781660A1 (en) 2011-06-03
US20210284627A1 (en) 2021-09-16
IL220009A0 (en) 2012-07-31
PT2505586E (pt) 2016-06-03
RU2012126129A (ru) 2013-12-27
SMT201600258B (it) 2016-08-31
CO6541645A2 (es) 2012-10-16
US20180362506A1 (en) 2018-12-20
JP2021091718A (ja) 2021-06-17
EP2505586B1 (en) 2016-03-02
KR20120096540A (ko) 2012-08-30
WO2011065402A1 (ja) 2011-06-03
BR112012012529A2 (pt) 2016-05-03
US20130116240A1 (en) 2013-05-09
JP2020079276A (ja) 2020-05-28
HUE028016T2 (en) 2016-11-28
NZ600840A (en) 2014-01-31
CN102712624A (zh) 2012-10-03
TWI491591B (zh) 2015-07-11
DK2505586T3 (en) 2016-05-30
ME02447B (me) 2016-09-20
TW201124378A (en) 2011-07-16
EP2505586A4 (en) 2013-05-15
SI2505586T1 (sl) 2016-08-31
AU2010323579A1 (en) 2012-07-19
BR112012012529B1 (pt) 2021-10-26
EP2505586A1 (en) 2012-10-03

Similar Documents

Publication Publication Date Title
RS54910B1 (sr) Jedinjenje indola i njegova upotreba u farmaciji
MX2012015023A (es) Derivado novedoso de nicotinamida o sal del mismo.
RS54776B1 (sr) Fosforoamidatni derivati 5-fluoro-2'-dezoksiuridina za upotrebu u tretmanu kancera
ES2618003T3 (es) Compuestos tricíclicos sustituidos como inhibidores de FGFR
NZ590297A (en) 2-Alkylamino-7,8-dihydropteridin-6(5H)-one and 2-alkylamino-8,9-dihydro-5H-pyrimido[4,5-b][1,4]diazepin-6(7H)-one derivatives
CY1120478T1 (el) Παραγωγα 2,6-υποκατεστημενης πουρινης και η χρηση αυτων στην αγωγη υπερπλαστικων διαταραχων
ES2600636T3 (es) Spiro-[1,3]-oxazinas y spiro-[1,4]-oxazepinas como inhibidores de BACE1 y/o BACE2
CY1119220T1 (el) Μονοκυκλικο παραγωγο πυριδινης
PH12016502154B1 (en) Pyridazinone herbicides
RS53416B (sr) Derivati benzofurana
JP2011132222A5 (sr)
MY143370A (en) Fused quinoline derivative and use thereof
PE20130229A1 (es) Derivados de piperidinona como inhibidores mdm2 para el tratamiento de cancer
AR084976A1 (es) Compuestos de bifenileno sustituidos y metodos de uso de los mismos para el tratamiento de enfermedades virales
PE20130155A1 (es) Derivados de ariletinilo
HRP20130851T1 (hr) Adicijske soli amina koji sadrže hidroksilne i/ili karboksilne grupe s derivatima aminonikotinske kiseline kao dhodh inhibitorima
CY1114067T1 (el) Παραγωγα πυρρολιδιν-2-ονης ως ρυθμιστες υποδοχεα ανδρογονων
RS54288B1 (sr) Supstituisani triazolopiridini i njihovo korišćenje kao ttk inhibitora
AR076579A1 (es) Espironucleosidos uracilicos oxetanicos, composiciones farmaceuticas que los contienen y uso de los mismos como inhibidores del virus de la hepatitis c (vhc).
NO20092770L (no) Nye aminopyrimidinderivater som PLK1-inhibitorer
ES2630079T3 (es) Moduladores de la ruta del complemento y usos de los mismos
CO6190626A2 (es) Compuestos y composiciones como inhibidores de proteasa activadora de canal
MY143605A (en) Tri-, tetra-substituted-3-aminopyrrolidine derivative
MX360667B (es) Derivados de etinilo como moduladores alostericos del receptor de glutamato metabotropico del subtipo 5 (mglur5).
ATE510829T1 (de) Neue verbindungen als adenosin-a1-rezeptor- antagonisten